Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Controlled-release dosage forms enhance the safety, efficacy, and reliability of drug therapy. They regulate the drug release rate to control drug action and reduce the frequency of drug administration to encourage patients to comply with dosing instructions. Conventional dosage forms often lead to wide swings in serumdrug concentrations. Most of the drug content is released soon after administration, causing drug levels in the body to rise rapidly, peak, and then decline sharply. For drugs whose actions correlate with their serumdrug concentration, these sharp fluctuations often cause unacceptable side effects at the peaks, followed by inadequate therapy at the troughs (Fig. 1). Administering smaller doses at more frequent intervals can damp concentration fluctuations, preventing over-and underdosing, but the inconvenience may cause patients to skip or delay doses, degrading efficacy. Compliance, measured as the percentage of patients taking 95% to 105% of prescribed oral medications, decreased from 67% with once-a-day regimens to 22% with four-times-a-day regimens (1). These difficulties are especially pronounced with drugs that have short half-lives and a narrow range of safe and effective concentrations. Precisely controlled release is particularly valuable for such agents (see Drug delivery systems).The term controlled release technology generally refers to a variety of methods used to exert various degrees of control over drug release. The U.S. Food and Drug Administration (FDA) defines controlled release dosage forms as those formulations designed to release active ingredient(s) at rates that differ significantly from their corresponding immediate release forms (2). The indexing system of Index Medicus supports this broad definition by classifying these dosage forms as delayed-action preparations, and Excerpta Medica uses the index term sustained release preparations. The pharmaceutical literature contains a profusion of terms, including delayed-action, extended action, gradual release, prolonged release, protracted release, slow release, sustained release, depot, retard, and timed-release dosage forms, all emphasizing an increased duration of action (3).To avoid confusion, several researchers have incorporated therapeutic intention into the definition of controlled release (4-7). Thus, controlled-release pharmaceuticals release drugs in vivo according to a predictable, therapeutically rational, programmed rate to achieve the optimal drug concentration in the minimal time (4). Specification by release rate complements specification by quantity; jointly considered, they fix the duration of drug release. Therefore, the drug's duration of action can become a design property of a controlled release dosage form rather than an inherent pharmacokinetic property of the drug molecule.Under this more precise definition, controlled release drug delivery not only provides a predictable, patterned action, but controls the rate of drug release for a predetermined period. Controlled release systems deliver drugs at a con...
Controlled-release dosage forms enhance the safety, efficacy, and reliability of drug therapy. They regulate the drug release rate to control drug action and reduce the frequency of drug administration to encourage patients to comply with dosing instructions. Conventional dosage forms often lead to wide swings in serumdrug concentrations. Most of the drug content is released soon after administration, causing drug levels in the body to rise rapidly, peak, and then decline sharply. For drugs whose actions correlate with their serumdrug concentration, these sharp fluctuations often cause unacceptable side effects at the peaks, followed by inadequate therapy at the troughs (Fig. 1). Administering smaller doses at more frequent intervals can damp concentration fluctuations, preventing over-and underdosing, but the inconvenience may cause patients to skip or delay doses, degrading efficacy. Compliance, measured as the percentage of patients taking 95% to 105% of prescribed oral medications, decreased from 67% with once-a-day regimens to 22% with four-times-a-day regimens (1). These difficulties are especially pronounced with drugs that have short half-lives and a narrow range of safe and effective concentrations. Precisely controlled release is particularly valuable for such agents (see Drug delivery systems).The term controlled release technology generally refers to a variety of methods used to exert various degrees of control over drug release. The U.S. Food and Drug Administration (FDA) defines controlled release dosage forms as those formulations designed to release active ingredient(s) at rates that differ significantly from their corresponding immediate release forms (2). The indexing system of Index Medicus supports this broad definition by classifying these dosage forms as delayed-action preparations, and Excerpta Medica uses the index term sustained release preparations. The pharmaceutical literature contains a profusion of terms, including delayed-action, extended action, gradual release, prolonged release, protracted release, slow release, sustained release, depot, retard, and timed-release dosage forms, all emphasizing an increased duration of action (3).To avoid confusion, several researchers have incorporated therapeutic intention into the definition of controlled release (4-7). Thus, controlled-release pharmaceuticals release drugs in vivo according to a predictable, therapeutically rational, programmed rate to achieve the optimal drug concentration in the minimal time (4). Specification by release rate complements specification by quantity; jointly considered, they fix the duration of drug release. Therefore, the drug's duration of action can become a design property of a controlled release dosage form rather than an inherent pharmacokinetic property of the drug molecule.Under this more precise definition, controlled release drug delivery not only provides a predictable, patterned action, but controls the rate of drug release for a predetermined period. Controlled release systems deliver drugs at a con...
Glucosyloxyethyl methacrylate (GEMA) was copolymerized with butyl acrylate (BA) for the preparation of a biomedical pressure‐sensitive adhesive with pendant monosaccharides, for possible use in medical applications. The measurements of 180° peel strength, ball tack, and holding power for the GEMA–BA copolymer films revealed that the film at the GEMA content of 5 mol % has excellent pressure‐sensitive adhesive properties. Protein adsorption onto the GEMA–BA copolymer film hardly occurred due to very low interfacial free energy between its surface and water. Release profiles of vitamin B12 from the GEMA–BA copolymer film suggests that it is useful as a material for a transdermal therapeutic system. © 1995 John Wiley & Sons, Inc.
The magnitude, mismatch and temporal variations of the electrode-gel-skin interface impedance can cause problems in electrical impedance tomography (EIT) measurement. It is shown that at the high frequencies generally encountered in EIT the capacitive properties of the electrode interface, and especially those of the skin, are of primary importance. A wide range of techniques are reviewed that could possibly be used to minimise these problems. These techniques include the use of skin preparation, penetration enhancers, temperature and electrical impulses. Although several of these techniques appear very attractive, they are not without serious potential drawbacks. A combination of some of these techniques may well hold the key to success.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.